Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.79 |
| ▸ | HRH2 | P25021 | 2/20 | 0.79 |
| ▸ | HRH1 | P35367 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SCN1A | P35498 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291468 | 0.92 | HRH3 (0.92) | HRH3HRH2HRH1ALDH1A1MAPK1 | |
| SCHEMBL8795398 | 0.91 | HRH3 (0.84) | HRH3HRH2HRH1ALDH1A1MAPK1 | |
| SCHEMBL1714312 | 0.89 | HRH3 (0.71) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL14714916 | 0.88 | HRH3 (1.00) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL4874490 | 0.85 | HRH3 (0.82) | HRH3HRH2HRH1LTA4HKDM4E | |
| SCHEMBL3566247 | 0.84 | NPC1 (0.62) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL5214906 | 0.84 | CA12 (0.63) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL5623066 | 0.84 | HRH3 (0.79) | HRH3HRH2HRH1 | |
| SCHEMBL227297 | 0.84 | HRH3 (0.85) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL14577989 | 0.83 | NPC1 (0.69) | HRH3NPC1RAB9ALTA4HCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1869088-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | Biogen Idec MA Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006104922-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | BIOGEN IDEC MA INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-6008226-A | AN ENZYME INHIBITOR OF C-GMP-PHOSPHODIESTERASE FOR TREATING HEART FAILURE, HYPERTENSION, REVERSING OR REDUCING NITRATE-INDUCED TOLERANCE AND ANGINA PECTORIS, CONGESTIVE HEART DISEASE AND MYOCARDIAL INFARCTION | SANOFI-SYNTHELABO (FR) | 1999-12-28 | — | — | US | disclosed |
| EP-0813410-A4 | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0813410-A1 | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5614530-A | GMP PHOSPHODIESTERASE INHIBITOR, HYPOTENSIVE | STERLING WINTHROP INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996028159-A1 | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | HRH3 2457/4885HRH2 2971/4885HRH1 3050/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HRH3 3491/4885HRH2 2813/4885HRH1 3698/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | HRH3 3491/4885HRH2 2813/4885HRH1 3698/4885 |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HRH3 3491/4885HRH2 2813/4885HRH1 3698/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HRH3 3491/4885HRH2 2813/4885HRH1 3698/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | HRH3 4794/4885HRH2 4460/4885HRH1 4670/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HRH3 3491/4885HRH2 2813/4885HRH1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.